Zavante Therapeutics Secures $45,000,000 Series A Funding

  • Feed Type
  • Date
  • Company Name
    Zavante Therapeutics
  • Mailing Address
    12670 High Bluff Dr. San Diego, CA 92130 USA
  • Company Description
    We are passionately committed to our mission to improve patients’ lives by identifying, developing and commercializing novel therapeutics addressing significant unmet medical needs in the hospital setting.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    The company has closed a $45 million Series A financing, consisting of $35 million from new investors and $10 million from the conversion of outstanding convertible notes. Proceeds from the financing will be used for the development of the Company’s lead product candidate, ZTI-01 (fosfomycin for injection), an injectable antibiotic with a differentiated mechanism of action designed for use in the hospital setting. In the second quarter of 2016, Zavante plans to initiate the ZEUS Study, a single pivotal clinical trial for ZTI-01, a first-in-class broad spectrum IV antibiotic under development to treat multidrug resistant (MDR) pathogens.
  • M&A Terms
  • Venture Investor
    Frazier Healthcare Partners
  • Venture Investor
    Longitude Capital Management
  • Venture Investor
    Aisling Capital

Trending on Xconomy